Serum levels of neuron-specific enolase in patients with fibromyalgia syndrome: Correlation with cognitive functions, quality of life and psychological state

Basit Öğe Kaydı
dc.contributor.authorVerim, Sabahattin
dc.contributor.authorBatmaz, Ibrahim
dc.contributor.authorYazmalar, Levent
dc.contributor.authorNas, Kemal
dc.contributor.authorCavas, Husamettin
dc.contributor.authorCevik, Remzi
dc.date.accessioned2024-04-24T17:20:41Z
dc.date.available2024-04-24T17:20:41Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND: Fibromyalgia syndrome (FMS) is a non-articular rheumatic disorder of unclear etiology, characterized by widespread body pain, fatigue and, psychological complaints OBJECTIVES: To investigate the serum levels of neuron-specific enolase (NSE) in patients with FMS and to evaluate the relationship between cognitive function, quality of life and psychological state. MATERIALS AND METHODS: Fifty-five female patients diagnosed with fibromyalgia according to the American College of Rheumatology (ACR) classification criteria, and 40 healthy female subjects were enrolled in the study. Life quality scale [(Fibromyalgia Impact Questionnaire (FIQ)], psychological state (Beck Depression Scale), and cognitive dysfunction (mini mental test, clock drawing test) scales were used for patients and control subjects. Serum NSE levels were studied using the ECLIA method. RESULTS: No significant differences were found in the serum NSE levels between the FMS patients and the control subjects (p > 0.05). Life quality and psychological state scores were found to be higher in FMS patients relative to the control group (p < 0.001). However, no significant differences were detected in cognitive function (p > 0.05). Significant correlations were not found between the serum NSE levels and quality of life, psychological state and cognitive functions (p > 0.05). CONCLUSION: No significant difference was determined between the groups in terms of NSE levels. Further studies, including larger series, should be carried out to clarify this relationship.en_US
dc.identifier.doi10.3233/BMR-160730
dc.identifier.endpage174en_US
dc.identifier.issn1053-8127
dc.identifier.issn1878-6324
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85048014370
dc.identifier.scopusqualityQ2
dc.identifier.startpage171en_US
dc.identifier.urihttps://doi.org/10.3233/BMR-160730
dc.identifier.urihttps://hdl.handle.net/11468/19199
dc.identifier.volume30en_US
dc.identifier.wosWOS:000391751500021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherIos Pressen_US
dc.relation.ispartofJournal of Back and Musculoskeletal Rehabilitation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFibromyalgia Syndromeen_US
dc.subjectNeuron-Specific Enolaseen_US
dc.subjectCognitive Dysfunctionen_US
dc.subjectQuality Of Lifeen_US
dc.subjectPsychological Stateen_US
dc.titleSerum levels of neuron-specific enolase in patients with fibromyalgia syndrome: Correlation with cognitive functions, quality of life and psychological stateen_US
dc.titleSerum levels of neuron-specific enolase in patients with fibromyalgia syndrome: Correlation with cognitive functions, quality of life and psychological state
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu